|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-9-4
|
|
pubmed:abstractText |
In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p < 0.05). Similar results were also observed in the Thal+Dex cohort. For the first time, our primary data suggested that the polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in MM.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1246-9
|
|
pubmed:meshHeading |
pubmed-meshheading:17666363-Adult,
pubmed-meshheading:17666363-Aged,
pubmed-meshheading:17666363-Aged, 80 and over,
pubmed-meshheading:17666363-Angiogenesis Inhibitors,
pubmed-meshheading:17666363-Anti-Inflammatory Agents,
pubmed-meshheading:17666363-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:17666363-Dexamethasone,
pubmed-meshheading:17666363-Drug Therapy, Combination,
pubmed-meshheading:17666363-Female,
pubmed-meshheading:17666363-Humans,
pubmed-meshheading:17666363-Male,
pubmed-meshheading:17666363-Middle Aged,
pubmed-meshheading:17666363-Mixed Function Oxygenases,
pubmed-meshheading:17666363-Multiple Myeloma,
pubmed-meshheading:17666363-Polymorphism, Genetic,
pubmed-meshheading:17666363-Thalidomide
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma.
|
|
pubmed:affiliation |
Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR China.
|
|
pubmed:publicationType |
Journal Article
|
